New lines in therapy of Raynaud's phenomenon

Rheumatology International

Volumn 29, Issue 4, 2009, Pages 355-363

  Lambova, Sevdalina Nikolova ^a   Müller Ladner, Ulf ^b,c  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c KERCKHOFF HEART CENTER   (Germany)

Author keywords

Endothelin 1 receptor antagonists; Prostacyclin; Raynaud's phenomenon; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBRISENTAN; ANTICOAGULANT AGENT; ARGININE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DILTIAZEM; FASUDIL; FELODIPINE; GINKGO BILOBA EXTRACT; GLYCERIL TRINITRATE; GLYCERYL TRINITRATE; ILOPROST; LOSARTAN; NIFEDIPINE; NITRATE; OPC 28326; PENTOXIFYLLINE; PLACEBO; PRAZOSIN; PROSTACYCLIN; PROSTAGLANDIN E1; SILDENAFIL; SITAXSENTAN; SULFONAMIDE; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST;

ACUPUNCTURE; ANKLE EDEMA; ANTIOXIDANT ACTIVITY; ARTHRALGIA; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEBRIDEMENT; DIARRHEA; DIET SUPPLEMENTATION; DIGITAL ULCER; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; ERYTHEMA; FEVER; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE PAIN; LOW LEVEL LASER THERAPY; MYALGIA; NAUSEA; ORTHOSTATIC HYPERTENSION; PATIENT EDUCATION; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; ULCER; UNSPECIFIED SIDE EFFECT; VOMITING;

ENDOTHELIN-1; EPOPROSTENOL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; RECEPTOR, ENDOTHELIN A; TREATMENT OUTCOME;

EID: 59449090964     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0792-4     Document Type: Review

References (81)

1. AL Herrick 2003 Treatment of Raynaud's phenomenon: new insights and developments Curr Rheumatol Rep 5 168 174
2. M Ho JJF Belch 1998 Raynaud's phenomenon: state of the art 1998 Scand J Rheumatol 27 319 322
3. SM Ling FM Wigley 1999 Raynaud's phenomenon in older adults. Diagnostic considerations and management Drugs Aging 15 3 183 195
4. AL Herric MM Cerrinic 2001 The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis Clin Exp Rheumatol 19 4 8
5. B Kahaleh O Meyer R Scorza 2003 Assessment of vascular involvement Clin Exp Rheumatol 21 S29 S9 S14
6. S Rajagopalan D Pfenninger C Kehrer 2003 Increased asymmetric dimethylarginine and endotheline-1 levels in secondary Raynaud's phenomenon Arthritis Rheum 48 7 1992 2000
7. L Schachna FM Wigley 2002 Targeting mediators of vascular injury in scleroderma Curr Opin Rheumatol 14 686 693
8. JA Block W Sequeira 2001 Raynaud's phenomenon Semin Lancet 357 2042 2048
9. Lisse JR. Raynaud's phenomenon. eMedicine./www.emedicine.com/med/ topic1993.htm, last updated 5 April 2006
10. FM Wigley 2002 Raynaud's phenomenon N Engl J Med 347 13 1001 1007
11. AE Thompson JE Pope 2005 Calcium-channel blockers for primary Raynaud's phenomenon: a meta-analysis Rheumatology 44 145 150
12. AE Thompson B Shea V Welch 2001 Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis Arthritis Rheum 44 8 1841 1847
13. C Leighton 2001 Drug treatment in scleroderma Drugs 61 3 419 427
14. WC Little CP Cheng 1994 Vascular versus myocardial effects of calcium antagonists Drugs 47 Suppl 4 41 45
15. S Lambova L Sapundziev 2007 Comparative study of therapeutic effect of diltiazem, nifedipine and felodipine in patients with primary and secondary Raynaud's phenomenon Scripta Scientifica Medica Varna 39 1 31 34
16. R Berkels D Taubert A Rosenkranz R Rösen 2003 Vascular protective effects of dihydropyridine calcium antagonists. Involvement of endothelial nitric oxide Pharmacology 69 171 176
17. MC Verhaar ML Honing T van Dam 1999 Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids Cardiovasc Res 42 752 760
18. P Maddison 2002 Prevention of vascular damage in scleroderma with angiotensin-converting enzyme inhibition Rheumatology 41 965 971
19. CP Tiefenbacher S Friedrich T Bleeke 2004 ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles Am J Physiol Heart Circ Physiol 286 H1425 H1432
20. M Dziadzio CP Denton R Smith 1999 Losartan therapy for Raynaud's phenomenon and scleroderma Arthritis Rheum 42 12 2646 2655
21. DB Badesch 2000 Continuous intravenous Epoprostenol for pulmonary hypertension due to the scleroderma spectrum disease Ann Intern Med 132 425 434
22. VV McLaughlin SP Gaine RJ Barst 2003 Efficacy and safety of Treprostinil: an Epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 293 299
23. L Bettoni A Geri P Airò 2002 Clinical systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years Clin Rheumatol 21 244 250
24. S Della Bella M Molteni C Mocellin 2001 Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules Prostaglandins Other Lipid Mediat 65 73 83
25. MP Mittag UF Beckheinrich 2001 Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels Acta Derm Venereol 81 294 297
26. R Scorza M Caronni B Mascagni 2001 Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study Clin Exp Rheumatol 19 503 508
27. S Lambova Kuzmanova St L Stoianova 2006 Therapy with iloprost in patients with severe Raynaud's phenomenon secondary to scleroderma Rheumatology 1 33 36
28. CM Black L Halkier-Sorensen JJ Belch 1998 Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, dosed-comparison study Br J Rheumatol 37 952 960
29. JJF Belch HA Capell ED Cooke 1995 Oral iloprost as a treatment for Raynaud's syndrome: a double-blind multicentre placebo-controlled study Ann Rheum Dis 54 197 200
30. N Galie M Humbert JL Vachiery 2002 Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 39 1496 1502
31. T Saji Y Ozawa T Ishikita 1996 Short term hemodynamic effect of a new oral PgI2 analogue, Beraprost, in pulmonary and secondary pulmonary hypertension Am J Cardiol 78 244 247
32. Y Kamata T Kamimura M Iwamoto S Minota 2005 Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis Clin Exp Dermatol 30 451
33. RJ Barst 2007 A review of pulmonary arterial hypertension: role of ambrisentan Vasc Health Risk Manag 3 1 11 22
34. CR Kumana GTY Cheung CS Lau 2004 Severe digital ischaemia treated with phosphodiesterase inhibitors Ann Rheum Dis 63 1522 1524
35. S Rosenkranz F Diet T Karasch 2003 Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and Raynaud's phenomenon Ann Int Med 139 10 871 873
36. M Baumhaekel P Scheffler M Boehm 2005 Use of tadalafil in patient with secondary Raynaud's phenomenon not responding to sildenafil Microvasc Res 69 178 179
37. S Rajagopalan D Pfenninger E Sokmers 2003 Effects of cilostazol in patients with Raynaud's syndrome Am J Cardiol 92 1310 1315
38. F Boin M Wigley 2005 Understanding, assessing and treating Raynaud's phenomenon Curr Opin Rheumatol 17 752 760
39. MD Mayes 2003 Endothelin and endothelin receptor antagonists in systemic rheumatic diseases Arthritis Rheum 48 5 1190 1199
40. JH Korn M Mayes M Matucci Cerinic 2004 Digital ulcers in systemic sclerosis prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis Rheum 50 12 3985 3993
41. M Ramos-Casals P Brito-Zerón N Nardi 2004 Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis Rheumatology 43 11 1454 1456
42. AB Waxman 2007 A review of sitaxsentan sodium in patients with pulmonary arterial hypertension Vasc Health Risk Manag 3 1 151 157
43. N Galié D Badesch R Oudiz 2005 Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 3 529 535
44. H Vatter V Seifert 2006 Ambrisentan, a non-peptide endothelin receptor antagonist Cardiovasc Drug Rev 24 11 63 76
45. ME Anderson TL Moore S Hollis 2002 Digital vascular response to topical glyceril trinitrate as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis Rheumatology 41 3 324 328
46. KA Kirou MK Crow 2000
47. CM Rembold CR Ayers 2003 Oral l-arginine can reverse digital necrosis in Raynaud's phenomenon Mol Cell Biochem 244 1-2 139 141
48. AT Tucker RM Pearson ED Cooke N Benjamin 1999 Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial Lancet 354 9191 1670 1675
49. H Wollersheim T Thien J Fennis 1986 Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon Clin Pharmacol Ther 40 2 219 225
50. H Wollersheim T Thien 1988 Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects J Clin Pharmacol 28 12 1089 1093
51. NA Flavahan JP Cooke JT Shepherd PM Vanhoutte 1987 Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs J Pharmacol Exp Ther 241 2 361 365
52. MA Chotani S Flavahan S Mitra 2000 Silent alpha-2c-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries Am J Physiol Heart Circ Physiol 278 4 H1075 H1083
53. RA Wise FM Wigley B White 2004 Efficacy and tolerability of selective alpha-2c-adrenergic, c receptor blocker in recovery from cold-induced vasospasm in scleroderma patients Arthritis Rheum 50 12 3994 4001
54. PB Furspan S Chatterjee R Robert RR Freedman 2004 Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease Arthritis Rheum 50 5 1578 1585
55. PB Furspan S Chatterjee MD Mayes RR Freedman 2005 Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon Rheumatology 44 488 494
56. SR Bailey AH Eid S Mitra 2004 Rho-kinase mediates cold-induced constriction of cutaneous arteries: role of alpha 2C-adrenoreceptor translocation Circ Res 94 1367 1374
57. Y Fukumoto M Mohri K Inokuchi 2007 Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina J Cardiovasc Pharmacol 49 117 121
58. K Inokuchi A Ito Y Fukumoto T Matoba 2004 Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery J Cardiovasc Pharmacol 44 275 277
59. K Tanaka H Minami M Kota 2005 Treatment of cerebral vasospasm with intra-arterial fasudil hydrochloride Neurosurgery 56 214 223
60. Y Yamamoto I Ikegaki Y Sasaki T Uchida 2000 The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit J Cardiovasc Pharmacol 35 2 203 211
61. JL Cracowski PH Carpentier B Imbert 2002 Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon Arthritis Rheum 46 5 1319 1323
62. CP Denton TD Bunce MB Dorado 1999 Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon Rheumatology 38 309 315
63. ME Mavrikakis JP Lekakis CM Papamichael 2003 Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis Int J Vitam Nutr Res 73 1 3 7
64. AH Muir R Robb M McLaren 2002 The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo controlled trial Vasc Med 7 4 265 267
65. P Gasser B Martina B Dubler 1997 Reaction of capillary blood cell velocity in nailfold capillaries to l-carnitine in patients with vasospastic disease Drugs Exp Clin Res 23 1 39 43
66. CB Bunker G Terenghi DR Springall 1990 Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon Lancet 336 1530 1533
67. CB Bunker C Reavley DJ O'Shaughnessy PM Dowd 1993 Calcitonin-gene related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon Lancet 342 80 83
68. B Coleiro SE Marshall CP Denton 2001 Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine Rheumatology 40 1038 1043
69. G Ihler H Chami-Stemman 2003 7-oxo-DHEA and Raynaud's phenomenon Med Hypotheses 60 3 391 397
70. L Fraenkel Y Zhang CE Chaisson 1998 The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women Ann Intern Med 129 208 211
71. H Momoi F Ikomi T Ohhashi 2003 Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries Jpn J Physiol 53 193 203
72. J Lekakis C Papamichael M Mavrikakis 1998 Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis Am J Cardiol 82 1555 1557
73. AE Postlethwaite TM Chiang 2007 Platelet contribution to the pathogenesis of systemic sclerosis Curr Opin Rheumatol 19 574 579
74. PR Ames S Lupoli J Alves 1997 The coagulation/fibrinolytic balance in systemic sclerosis: evidence for a haematological stress syndrome Br J Rheumatol 36 1045 1050
75. CP Denton K Howell RJ Stratton CM Black 2000 Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study Clin Exp Rheumatol 18 4 499 502
76. MJ Fritzler DA Hart 1990 Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy Arthritis Rheum 33 2 274 276
77. C Cimminiello 1996 Clinical trials with defibrotide in vascular disorders Semin Thromb Hemost 22 Suppl 1 29 34
78. RT Eberhardt JD Coffman 2000 Drug treatment of peripheral vascular disease Heart Dis 2 1 62 74
79. M Hirschl R Katzenschlager C Francesconi M Kundi 2004 Low level laser therapy in primary Raynaud's phenomenon-results of a placebo-controlled, double-blind intervention Study J Rheumatol 31 2408 2412
80. M al-Awami M Schillinger T Maca 2004 Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon Vasa 33 25 29
81. B Balogh W Mayer M Vesely 2002 Adventitial stripping of the radial and ulnar arteries in Raynaud's disease J Hand Surg 27A 1073 1080